Familial atypical hemolytic uremic syndrome: A review of its genetic and clinical aspects

Fengxiao Bu, Nicolo Borsa, Ardissino Gianluigi, Richard J H Smith

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare renal disease (two per one million in the USA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Both sporadic (80 of cases) and familial (20 of cases) forms are recognized. The study of familial aHUS has implicated genetic variation in multiple genes in the complement system in disease pathogenesis, helping to define the mechanism whereby complement dysregulation at the cell surface level leads to both sporadic and familial disease. This understanding has culminated in the use of Eculizumab as first-line therapy in disease treatment, significantly changing the care and prognosis of affected patients. However, even with this bright outlook, major challenges remain to understand the complexity of aHUS at the genetic level. It is possible that a more detailed picture of aHUS can be translated to an improved understanding of disease penetrance, which is highly variable, and response to therapy, both in the short and long terms.

Original languageEnglish
Article number370426
JournalClinical and Developmental Immunology
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Penetrance
Hemolytic Anemia
Rare Diseases
Acute Kidney Injury
Thrombocytopenia
Therapeutics
Kidney
Atypical Hemolytic Uremic Syndrome
Genes
eculizumab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Familial atypical hemolytic uremic syndrome : A review of its genetic and clinical aspects. / Bu, Fengxiao; Borsa, Nicolo; Gianluigi, Ardissino; Smith, Richard J H.

In: Clinical and Developmental Immunology, Vol. 2012, 370426, 2012.

Research output: Contribution to journalArticle

@article{74429e49fb8b473f9cfee1c179b63687,
title = "Familial atypical hemolytic uremic syndrome: A review of its genetic and clinical aspects",
abstract = "Atypical hemolytic uremic syndrome (aHUS) is a rare renal disease (two per one million in the USA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Both sporadic (80 of cases) and familial (20 of cases) forms are recognized. The study of familial aHUS has implicated genetic variation in multiple genes in the complement system in disease pathogenesis, helping to define the mechanism whereby complement dysregulation at the cell surface level leads to both sporadic and familial disease. This understanding has culminated in the use of Eculizumab as first-line therapy in disease treatment, significantly changing the care and prognosis of affected patients. However, even with this bright outlook, major challenges remain to understand the complexity of aHUS at the genetic level. It is possible that a more detailed picture of aHUS can be translated to an improved understanding of disease penetrance, which is highly variable, and response to therapy, both in the short and long terms.",
author = "Fengxiao Bu and Nicolo Borsa and Ardissino Gianluigi and Smith, {Richard J H}",
year = "2012",
doi = "10.1155/2012/370426",
language = "English",
volume = "2012",
journal = "Clinical and Developmental Immunology",
issn = "1740-2522",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Familial atypical hemolytic uremic syndrome

T2 - A review of its genetic and clinical aspects

AU - Bu, Fengxiao

AU - Borsa, Nicolo

AU - Gianluigi, Ardissino

AU - Smith, Richard J H

PY - 2012

Y1 - 2012

N2 - Atypical hemolytic uremic syndrome (aHUS) is a rare renal disease (two per one million in the USA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Both sporadic (80 of cases) and familial (20 of cases) forms are recognized. The study of familial aHUS has implicated genetic variation in multiple genes in the complement system in disease pathogenesis, helping to define the mechanism whereby complement dysregulation at the cell surface level leads to both sporadic and familial disease. This understanding has culminated in the use of Eculizumab as first-line therapy in disease treatment, significantly changing the care and prognosis of affected patients. However, even with this bright outlook, major challenges remain to understand the complexity of aHUS at the genetic level. It is possible that a more detailed picture of aHUS can be translated to an improved understanding of disease penetrance, which is highly variable, and response to therapy, both in the short and long terms.

AB - Atypical hemolytic uremic syndrome (aHUS) is a rare renal disease (two per one million in the USA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Both sporadic (80 of cases) and familial (20 of cases) forms are recognized. The study of familial aHUS has implicated genetic variation in multiple genes in the complement system in disease pathogenesis, helping to define the mechanism whereby complement dysregulation at the cell surface level leads to both sporadic and familial disease. This understanding has culminated in the use of Eculizumab as first-line therapy in disease treatment, significantly changing the care and prognosis of affected patients. However, even with this bright outlook, major challenges remain to understand the complexity of aHUS at the genetic level. It is possible that a more detailed picture of aHUS can be translated to an improved understanding of disease penetrance, which is highly variable, and response to therapy, both in the short and long terms.

UR - http://www.scopus.com/inward/record.url?scp=84870161177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870161177&partnerID=8YFLogxK

U2 - 10.1155/2012/370426

DO - 10.1155/2012/370426

M3 - Article

C2 - 23251215

AN - SCOPUS:84870161177

VL - 2012

JO - Clinical and Developmental Immunology

JF - Clinical and Developmental Immunology

SN - 1740-2522

M1 - 370426

ER -